S Cristofanon
Overview
Explore the profile of S Cristofanon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
444
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Cristofanon S, Abhari B, Krueger M, Tchoghandjian A, Momma S, Calaminus C, et al.
Cell Death Dis
. 2015 Apr;
6:e1724.
PMID: 25880091
This study aims at evaluating the combination of the tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL)-receptor 2 (TRAIL-R2)-specific antibody Drozitumab and the Smac mimetic BV6 in preclinical glioblastoma models. To this end, the...
3.
Basit F, Cristofanon S, Fulda S
Cell Death Differ
. 2013 Jun;
20(9):1161-73.
PMID: 23744296
Obatoclax (GX15-070), a small-molecule inhibitor of antiapoptotic Bcl-2 proteins, has been reported to trigger cell death via autophagy. However, the underlying molecular mechanisms have remained elusive. Here, we identify GX15-070-stimulated...
4.
Cristofanon S, Fulda S
Cell Death Dis
. 2012 Nov;
3:e432.
PMID: 23190604
To search for novel strategies to enhance the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis pathways in glioblastoma, we used the B-cell lymphoma 2/Bcl2-like 2-inhibitor ABT-737. Here we report that...
5.
Abhari B, Cristofanon S, Kappler R, von Schweinitz D, Humphreys R, Fulda S
Oncogene
. 2012 Aug;
32(27):3263-73.
PMID: 22890322
Inhibitor of apoptosis (IAP) proteins represent promising therapeutic targets due to their high expression in many cancers. Here, we report that small-molecule IAP inhibitors at subtoxic concentrations cooperate with monoclonal...
6.
Wagner L, Marschall V, Karl S, Cristofanon S, Zobel K, Deshayes K, et al.
Oncogene
. 2012 Apr;
32(8):988-97.
PMID: 22469979
Inhibitor of apoptosis (IAP) proteins are expressed at high levels in many cancers and therefore represent attractive targets for therapeutic intervention. Here, we report for the first time that the...
7.
Gonzalez P, Mader I, Tchoghandjian A, Enzenmuller S, Cristofanon S, Basit F, et al.
Cell Death Differ
. 2012 Feb;
19(8):1337-46.
PMID: 22343715
In this study, we report a novel mechanism of action for a cytotoxic derivative of betulinic acid (BA). B10 is a semi-synthetic glycosylated derivative of BA selected for its enhanced...
8.
Bangert A, Cristofanon S, Eckhardt I, Abhari B, Kolodziej S, Hacker S, et al.
Oncogene
. 2012 Jan;
31(44):4677-88.
PMID: 22266862
Glioblastoma is the most common primary brain tumor with a very poor prognosis, calling for novel treatment strategies. Here, we provide first evidence that histone deacetylase inhibitors (HDACI) prime glioblastoma...
9.
Loder S, Fakler M, Schoeneberger H, Cristofanon S, Leibacher J, Vanlangenakker N, et al.
Leukemia
. 2011 Dec;
26(5):1020-9.
PMID: 22173242
Evasion of apoptosis may contribute to poor treatment response in pediatric acute lymphoblastic leukemia (ALL), calling for novel treatment strategies. Here, we report that inhibitors of apoptosis (IAPs) at subtoxic...
10.
Hacker S, Karl S, Mader I, Cristofanon S, Schweitzer T, Krauss J, et al.
Oncogene
. 2011 May;
30(19):2275-81.
PMID: 21562496
Despite aggressive therapies, the prognosis of children with high-risk medulloblastoma is still poor, thus underscoring the need to develop novel treatment strategies. Here, we report that histone deacetylase inhibitors (HDACI),...